Renaissance Technologies LLC Sells 196,700 Shares of BioAtla, Inc. $BCAB

Renaissance Technologies LLC trimmed its position in shares of BioAtla, Inc. (NASDAQ:BCAB) by 27.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 510,514 shares of the company’s stock after selling 196,700 shares during the period. Renaissance Technologies LLC owned approximately 30.81% of BioAtla worth $82,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Millennium Management LLC raised its position in shares of BioAtla by 123.4% in the 4th quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock valued at $433,000 after buying an additional 421,072 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of BioAtla during the 4th quarter worth approximately $104,000. Marshall Wace LLP bought a new position in BioAtla in the fourth quarter valued at approximately $508,000. Jane Street Group LLC increased its stake in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after acquiring an additional 123,597 shares during the last quarter. Finally, Susquehanna International Group LLP raised its position in BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares in the last quarter. 77.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $200.00.

BioAtla Stock Down 2.8%

BioAtla stock opened at $3.18 on Friday. BioAtla, Inc. has a 12-month low of $2.81 and a 12-month high of $71.50. The business’s 50-day moving average price is $3.62 and its two-hundred day moving average price is $5.43. The stock has a market cap of $5.28 million, a PE ratio of -0.12 and a beta of 0.78.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, August 13th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.64. The company had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.50 million.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.